Compare STEW & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STEW | WGS |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | United States |
| Employees | N/A | 1300 |
| Industry | Investment Managers | Retail: Computer Software & Peripheral Equipment |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | 1996 | N/A |
| Metric | STEW | WGS |
|---|---|---|
| Price | $18.03 | $69.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $120.71 |
| AVG Volume (30 Days) | 68.9K | ★ 653.2K |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $29.98 |
| Revenue Next Year | N/A | $25.92 |
| P/E Ratio | ★ N/A | $1,251.58 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.55 | $55.17 |
| 52 Week High | $18.67 | $170.87 |
| Indicator | STEW | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 65.27 | 50.92 |
| Support Level | $17.43 | $68.55 |
| Resistance Level | $18.34 | $95.75 |
| Average True Range (ATR) | 0.21 | 4.37 |
| MACD | 0.08 | 1.55 |
| Stochastic Oscillator | 82.40 | 76.72 |
SRH Total Return Fund, Inc. is a non-diversified closed-end management investment company. The company's investment objective is to seek total returns. Its fund utilizes a bottom-up, value-driven investment process to identify securities of good quality businesses trading below estimated intrinsic value. The Funds are available as an actively-managed closed-end fund, an actively managed ETF and a passively-managed ETF.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.